Starling Oncology, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
Starling Oncology, Inc. (DFPH) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $34.86 million as of 2024-06-30, per its 10-Q filed 2024-08-13.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2025-03-26
- 2024-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $34.86M.
- 2024-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $42.68M.
- 2023-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $72.15M.
- 2023-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $59.88M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2024-06-30 | $34.86M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $42.68M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $72.15M 10-K · filed 2025-03-26 |
| 2023-09-30 | $59.88M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $80.14M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $98.97M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $120.72M 10-K · filed 2024-03-28 |